This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutStudy Design1L study design2L+ study designEfficacy1L overall efficacy1L CNS efficacy1L 36-month overall efficacy1L 36-month CNS efficacy2L+ efficacySafetyPooled Safety: all lines1L safety2L+ safetyDosing & Therapy ManagementDosingTherapy management

The information on this website is based on data from adult patients with ALK-positive advanced NSCLC (anaplastic lymphoma kinase positive advanced non small cell lung cancer) treated with LORVIQUA▼(lorlatinib), produced in line with the LORVIQUA (lorlatinib) Summary of Product Characteristics.
LORVIQUA (lorlatinib) Prescribing Information click here.
▼LORVIQUA is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. Adverse event reporting information can also be found at the bottom of the page.

A once-daily oral treatment with flexible dosing to manage adverse reactions1

For special warnings and precautions for use, please see the LORVIQUA SmPC.

  • Treatment with LORVIQUA should be initiated and supervised by a physician experienced in the use of anticancer medicinal products.1
  • Detection of ALK-positive NSCLC is necessary for selection of patients for treatment with LORVIQUA 1
  • LORVIQUA should be swallowed whole, with or without food—never chewed, crushed, or split1
  • LORVIQUA is contraindicated in patients taking strong CYP3A4/5 inducers concomitantly* and in those with hypersensitivity to LORVIQUA or any of the excipients of LORVIQUA1
  • For patients taking LORVIQUA, alternative concomitant medicinal products with less potential to inhibit CYP3A4/5 should be considered1,*
  • Patients must avoid grapefruit products while taking LORVIQUA1
  • There are specific recommendations for dose modifications related to particular ARs1

 

*Please refer to the LORVIQUA SmPC for recommendations regarding the use of CYP3A4/5 inducers and CYP3A4/5 inhibitors.AR=adverse reaction; AV=atrioventricular; CNS=central nervous system; CYP3A4/5=cytochrome P450 3A4/5; ILD=interstitial lung disease; SmPC=Summary of Product Characteristics.ReferencesReference:

Pfizer. LORVIQUA (lorlatinib) Summary of Product Characteristics. 

Dosing & Therapy Management
LORVIQUA safety profile
 Review the safety Loading
LORVIQUA efficacy
 Discover the data Loading
PP-LOR-IRL-0076 February 2024 Legal Category S1A Further information available on request

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0784. June 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0784. June 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0784. June 2024